A radioimmunoassay suitable for measurement of 17aOH-progesterone concentrations in small aliquots of plasma (20 ILL), amniotic fluid (20 ILL) and saliva (200 ILL) is described. The assay features an antiserum raised against a 17aOH-progesterone-3-(O-carboxymethyl)oxime/BSA conjugate coupled to a magnetisable, solid-phase support; the homologous radioligand is a 125 1_ iodohistamine conjugate. This combination of a y-emitting ligand and a magneticseparation procedure has the advantage of reducing assay time and cost; it also allows processing of plasma and saliva samples in the same assay batch. The method has satisfactory sensitivity, precision and accuracy. Data derived from clinical studies of patients with congenital adrenal hyperplasia indicate the usefulness of this assay in routine practice.
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Measurement of 17aOH-progesterone in plasma.l-'' amniotic fluid" and more recently saliva 4 . 5 is now accepted to be of value in studies of patients with congenital adrenal hyperplasia (CAH) due to C-21 hydroxylase deficiency. Current assay procedures, which mainly rely on liquid-phase antiserum, a tritiated radioligand and dextran-coated charcoal for separating the bound and free fractions, have well-recognised limitations. A simplified immunoassay which couples the advantages associated with the use of an 125 1_ radioligand and a solid-phase first antibody has therefore been developed. Since it was envisaged that the same assay would be used for measurement of 17aOH-progesterone in plasma, amniotic fluid and saliva, the relatively low concentrations of this steroid in saliva imposed the need for high sensitivity. A high degree of specificity was also required for its use in amniotic fluid. Although comparatively few samples are required for the initial diagnosis of CAH, monitoring the effectiveness of glucocorticosteroid replacement therapy and checking patient compliance generates large sample numbers. Effective 'fast return' of data therefore imposes the further requirement for a high-throughput procedure.
In developing this assay for 17aOH-progesterone, cellulose contammg magnetisable particles was selected as the solid-phase support since previous experience suggested that this allowed development of systems having lower limits of sensitivity closely approximating to those achieved by 'classical' assay techniques.P-? This magnetisable support is also attractive because it avoids the need for timeconsuming centrifugation; the antibody-bound fraction being easily precipitated using a simple magnetic device. This assay, which has been in routine use for about 1 year, has been used for processing plasma samples received via the SAS service and in a research programme directed towards assessing the value of salivary sampling for monitoring glucocorticosteroid replacement in children with CAH due to C-21 hydroxylase deficiency. The laboratory also receives a significant number of samples of amniotic fluid, collected during the first trimester, for prenatal diagnosis in mothers who have previously had a child affected with CAH. by washing with sodium hydroxide (1 M) and then with distilled water prior to refraction ation. 17aHydroxyprogesterone and related steroids, bovine serum albumin (Cohn fraction V), gelatin (BP) and histamine were all obtained from Sigma London Chemical Co. Ltd, Poole, Dorset. Triton X-lOO was purchased from Koch-Light Laboratories Ltd, Bucks.
Materials and methods

REAGENTS FOR RADIOIMMUNOASSAYS
All common solvents and reagents (Analar
Silica gel pre-coated plastic sheets for thinlayer chromatography (Machery-Nagel Polygram Sil G/UV 254) were obtained from Camlab Ltd, Cambridge.
[ 125I]sodium iodide (IMS-30) was obtained from Amersham International pic, Amersham, Bucks.
Cyanogen bromide was purchased from Aldrich Chemical Co. pic, Gillingham, Dorset.
The magnetisable cellulose used throughout these studies was obtained from Serono Diagnostics, London. Although 'in-house' preparation of this support by a modification of the procedure of Dawes & Gardner" is possible, reduction to the required particle size requires relatively expensive crushing equipment.
Disposable polypropylene test tubes (75 x 12 mm) were obtained from the Boehringer Corporation Ltd, East Sussex and used as received. RADIOLIGAND 17aOH-progesterone-3-(O-carboxymethyl)-oxime, prepared by the procedure of Erlanger et al," was coupled to 125I-iodohistamine by a slight modification III of the methodology described by Hunter et al. II The iodinated steroid conjugate was chromatographed in the solvent system chloroform:methanol:acetic acid (90: 10:1 v/v) on silica gel plates. Following its location as a single peak of radioactivity, using a Berthold radiochromatogram scanner, the derivative was eluted with ethanol: This was stored at 4°C and was stable for at least 3 months. Before use, this radioligand was diluted in assay buffer (containing 0·02% Triton X-l(0) to give 40000 cpm nominal; i.e. the dilution corresponding to 40 000 cprn/mL on the day of preparation of the label.
17aoH-PROGESTERONE SOLUTIONS
A stock standard solution of 17aOHprogesterone, 1 mg in 10 mL, was stored at 4°C. Subsequent dilution with ethanol provided the working standards used in the dose-response curve: 25, 50, 100, 200, 300, 500 and 750 pg steroid in 10 IJ-L ethanol. 12 The antisera were titred, their cross-reactivity with progesterone assessed, and that antiserum having the lowest cross-reaction with progesterone was coupled to the solid-phase support.
Conjugation to the magnetisable cellulose was achieved in good yield (5D-60% based on assay tubes available) using a conventional cyanogen bromide activation technique. 13 The coupled antiserum, suitably diluted in assay buffer (0,01 M phosphate-buffered saline containing gelatin (0'1%), pH 7,4) was stable on storage at 4°C for at least 6 months. Prior to use, the antiserum was diluted (1:4000) in assay buffer.
ASSAY PROCEDURE
The procedures followed for processing plasma, amniotic fluid and saliva samples are outlined in Fig. I . Separation of the antibody bound/free steroid in a large batch of tubes (n=60) was rapidly achieved «4 min) using a tray having magnets sealed into the base (Serono Diagnostics Ltd). After inverting the tray the tubes were 'blotted' on absorbent tissue. This easy separation was complimented by rapid counting of the bound fraction in a multihead y-counter (NE 1600). The unknown 17aOH-progesterone concentrations in the samples were interpolated from the dose-response curve using the fourparameter fit model of Rodbard and Hutt.!"
Samples collected at between 14 and 20 weeks' gestation from mothers who were at risk of having an infant with a neural-tube defect were analysed. In each case, the pregnancy proceeded to term and a normal infant was delivered. Gestational ages were calculated from the dates of the last menstrual period and confirmed by measurement of the fetal biparietal diameter.
A further 12 amniotic fluid samples collected from mothers with previously affected CAH children (C-21 hydroxylase deficiency) were analysed.
Results
ANALYTICAL VARIABLES
The dose-response curve (Fig. 2) 
Plasma quality control samples
Inter-assay variation.
Intra-assay variation,
of having high 17aOH-progesterone concentrations were assayed both undiluted and diluted (1:6 v/v plasma:water). Measurement at these two concentrations ensured valid information from a single rather than a repeat assay. Since saliva samples were derived from a study of patients receiving replacement therapy they rarely required dilution prior to assay.
Precision of the dose-response curve was good, coefficients of variation (CY) of the response metameter (counts) not exceeding 4% at any fixed point. The lower limit of sensitivity of this curve was 5 pgltube corresponding to 750 pmollL in plasma and amniotic fluid (20 ILL aliquot) and proportionately less (75 pmol/L) in saliva. This sensitivity was strictly comparable to that of the 'classical' RIA, incorporating a tritiated label, used in our earlier studies. 15 obtained on assay of plasma and saliva samples with those of the 3H-RIA; the correlations were excellent, as shown below.
Plasma: n=45; r=O·9H9; P,=1·019 p'H-O·02 nmol/L. Saliva: n=20; r=O·9Hl; SI=1·023 S'H-4Q pmol/L.
PR!'CISION
Three pools of high, medium and low 17aOHprogesterone concentrations were established for plasma and saliva. Ten aliquots from each pool were assayed and the results used to assess intra-assay variation. These pools were split into aliquots, stored at -20°C and used as quality controls for subsequent assays thereby allowing assessment of inter-assay variation ( Table 2) . SPECIFICITY (Table 1) based on the criteria of Abraham Ih indicated that the coupling procedure did not have any markedly deleterious effect. The cross-reaction with progesterone (6'}'o) must be considered when interpreting the data from saliva and plasma samples of post-pubertal female patients and samples of amniotic fluid in late pregnancy.
Comparison of cross-reactivity
The specificity of the current procedure was further checked by comparing the results
SERIAL DILUTION
High titre samples of plasma and saliva, obtained from a poorly controlled patient with CAH, were diluted with distilled water and assayed. The data showed linear response (r p=0'999; r,=0'995) with non-significant intercepts.
Discussion
With the introduction of plasma, amniotic fluid and salivary sampling procedures into clinical practice.?" it is obviously advantageous to process these samples by a common methodology. That described here allowed measurement of 17aOH-progesterone (17aOHP) in small aliquots of plasma, amniotic fluid and saliva. Since the separation of the antibodybound and free moieties relied on precipitation of a magnetisable cellulose-coupled antiserum rather than on the use of dextran-coated charcoal, it was virtually independent of time and could be performed at room temperature. The assay was simple and large sample numbers (n=50) could be processed in one batch. This is a point of some importance because the number of requests for this assay is not consistent. Our laboratory, for example, receives numerous samples following a paediatric out-patient clinic, whereas at other times demand is low. Processing this large batch of mixed plasma and saliva samples in a one-day assay is therefore particularly attractive.
On the other hand, requests for amniotic fluid 17aOHP measurements are infrequent, but a rapid result is required for prenatal diagnosis. This assay can provide the required information within 1 day. Accumulating experience indicates that although measurement of 17aOH-progesterone in plasma is useful in the initial diagnosis of C-21 hydroxylase deficiency, isolated measurements are an inadequate index of control when monitoring glucocorticosteroid replacement therapy. lS ince it is often possible to collect only single blood samples in infants and children, the results are critically dependent not only on the timing of the sample collected in relation to the previous steroid dose, but also on changes in circulating steroid concentrations caused by circadian rhythms in pituitary-adrenal activity. Data presented in Fig. 3 illustrate the marked variation in plasma 17aOH-progesterone values with time in a poorly controlled CAH patient. The critical variation with time makes salivary sampling a particularly attractive alternative method, since patients can collect multiple serial samples throughout the day. Children aged 2 years can easily salivate directly into small tubes, which can be stored deep frozen at home until brought to the clinic for processing.
The relationship between 17aOH-progesterone concentrations in matched samples of plasma and saliva provided by a group of treated CAH patients is illustrated in Fig. 4 . Although the degree of control in these patients varied, there was a highly significant correlation in plasma and salivary values over a wide range of 17aOH-progesterone concentrations. Treatment was judged to be adequate in those patients having concentrations of this steroid in plasma and saliva which did not exceed 40 nmollL and 15(Xl pmollL respectively. Figure 5 illustrates the detailed information obtained on processing saliva samples collected at frequent intervals for 24-hour time spans. Since the half-life of cortisol is relatively short, replacement therapy usually requires thricedaily administration. As most children receive their last dose at around 22·00 h, it is not surprising to observe that some patients have markedly elevated 17aOH-progesterone values in their early-morning saliva samples. Experience has shown that this excessive surge in adrenal activity can be reduced to .acceptable limits by administrating an equivalent dose of a longer acting synthetic steroid, e.g. prednisolone, at night, whilst maintaining daytime therapy with cortisol.
The concentrations of 17aOH-progesterone in amniotic fluid samples from normal pregnant women (controls) and from those at risk for 6 . The concentrations ranged from 10 to 29 nmol/L in 70 samples collected from normal pregnancies (mean±SD, lX·6±5·2 nrnol/L). In nine pregnancies at risk for C-2l hydroxylase deficiency, amniotic fluid l70H-progesterone concentrations were within the normal range.
Information on the outcome of these pregnancies was subsequently available, and all infants were clinically and biochemically normal. In a further three pregnancies at risk, concentrations of l7aOH-progesterone were elevated. Two pregnancies proceeded to term, and in each case, a virilized female infant was born. C-21 hydroxylase deficiency was confirmed by demonstrating a markedly elevated plasma 17aOH-progesterone concentration. In the third pregnancy (denoted by symbol. in the figure) , the parents elected to terminate. On examination of the abortus, there was c1itoromegaly in a female fetus and histological examination of the adrenals showed marked hyperplasia of the fetal zone. No fetal serum sample was available for steroid analysis.
Thus the amniotic fluid assay is reliable, based on the analysis of samples collected from 70 controls and 12 pregnancies at risk for CAH due to C-21 hydroxylase deficiency, and therefore confirms previous studies on the prenatal diagnosis of CAH.-1.17.1K
These detailed studies of 'control' in CAH patients based on salivary rather than plasma sampling have been facilitated by the development of the simplified immunoassay described here. This assay has also done much to resolve problems in the laboratory associated with fluctuations in demand for analyses of 17aOHprogesterone in the three matrices described, and the need to process several aliquots of samples to cope with the broad dynamic range of possible 17aOH-progesterone concentrations.
